Known as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults[…]
Almotriptan Patent to Expire in May 2015
Anti-Migraine, Drug Research & Development API, Patent Expiration 2015 Tags: migraine headachesserotonin May 05, 2015
Triptorelin Acetate is Effective On and Off Label
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2015 Tags: prostate cancer Nov 12, 2012
Used to treat the symptoms of prostate cancer, Triptorelin Acetate CAS# 149194-24-7 is a man-made form of a hormone that regulates many functions in the body. Triptorelin is effectual at over stimulating the body’s own production of these specific hormones, therefore causing the production of these hormones to shut down. This shut down is triggered[…]
Oxybutynin Chloride Offers Hope for Patients with Bladder Conditions
Antispasticity Agent, Drug Research & Development API, Patent Expiration 2015 Tags: anticholinergicoveractive bladder Oct 25, 2012
Oxybutynin Chloride is an antispasmodic and anticholinergic medication. Effective for the treatment of a variety of bladder conditions, such as overactive bladder, detrusor instability, detrusor hyperreflexia, spasmodic bladder, unstable bladder, irritable bladder, incontinence and bladder spasms, the brand name for this medication is Ditropan XL. Ortho-McNeil Pharmaceutical Inc. markets oxybutynin chloride as Ditropan XL, with[…]
Oxybutynin, a Solution for Overactive Bladder Condition?
Antispasticity Agent, Drug Research & Development API, Patent Expiration 2015 Tags: anticholinergicoveractive bladder Oct 18, 2012
Oxybutynin, CAS# 5633-20-5, is known as the brand name Oxytrol. Marketed by Watson, this medication used to treat overactive bladder has a patent expiration of Apr 26, 2015. As an industry standard used to treat the symptoms of overactive bladder, also known as OAB, oxybutynin has proven to be both efficacious and safe. As the[…]
Lidocaine and Tetracaine Work Together in a Novel Anesthetic Patch
Anesthetic, Patent Expiration 2015 Oct 17, 2012
Known as Synera, which is marketed by Nuvo Research and ZARS Pharmaceutical Inc., this topical anesthetic patch is due to have a patent expiration on July 28, 2015. The generic ingredients of both Lidocaine CAS# 137-58-6, and Tetracaine CAS# 94-24-6 are projected to be sought after as researchers clamor to create generic alternatives of this[…]
Why Octreotide Acetate is the Worlds Most Prescribed Somatostatin Analogue
Chemotherapeutic / Anti-Neoplastic, Gastrointestinal Agent, Hormonal Agent, Patent Expiration 2015 Oct 15, 2012
Octreotide Acetate is known as the brand name Sandostatin, which is marketed by Novartis. With the patent for sandostatin expiring on May 18, 2015, the opportunities are wide open for researchers seeking to develop a generic form of this number one prescribed somatostatin analogue in the world. Octreotide acetate is a man-made protein which is similar[…]
Gemifloxacin Mesylate – a Powerful Opponent for Drug Resistant Bacteria
Antibacterial, Antibiotic, Drug Research & Development API, Patent Expiration 2015 Tags: antibioticDNA Oct 01, 2012
Gemifloxacin Mesylate is a reliable and effectual antibiotic. Known as Factive, which is marketed by LG Life Sciences, the patent for gemifloxacin mesylate is due to expire on June 15, 2015. This once daily, 320 milligram tablet is the only FDA approved drug indicated for the treatment of acute bacterial exacerbation of chronic bronchitis caused[…]
Fight Fungal Infections and Prostate Cancer with Itraconazole
Anti-Fungal, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2015 Tags: prostate cancer Sep 25, 2012
Itraconazole is an azole antifungal medicine. Known as the brand name Sporanox, which is marketed Janssen, the patent for this potent product expires on January 13, 2015. Itraconazole works by interfering with the formation of the fungal cell membrane. It is a formidable product for treating infections caused by fungus, which can invade any part[…]
Trandolapril is Effectual and Profitable
Cardiovascular Agent, Drug Research & Development API, Patent Expiration 2015, Respiratory Tract Agent Tags: heart failure Sep 20, 2012
Trandolapril is intended for patients with hypertension, or for anyone who has experienced heart failure post myocardial infarction. Particularly effective for those patients who have left-ventricular dysfunction after a heart attack, trandolapril is an angiotensin-converting enzyme, or ACE inhibitor. Marketed by Abbott as the brand name Mavik, the patent for this lifesaving medication is due[…]
Gatifloxacin Is An Available and Effective Antibiotic
Antibiotic, Bulk Active Ingredient, Patent Expiration 2015, TEVA API Tags: antibioticChinaDNAophthalmic Sep 19, 2012
Gatifloxacin is a quinolone antibiotic also known as Tequin. While Tequin, which is marketed by Bristol- Myers Squibb is no longer sold as a tablet in the U.S., it is still sold in other countries in tablet form, like China. In the United States gatifloxacin is sold as an opthalmic solution, also known as Zymar,[…]
